We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
1ADNB | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADO | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1ADOA | AdAlta Limited | 0.001 | 0.00 | 0.00% | 0.00 | 0 |
1AE | Aurora Energy Metals Ltd | 0.061 | 0.00 | 0.00% | 0.00 | 0 |
1ADNA | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADN | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14D | 1414 Degrees Limited | 0.035 | 0.00 | 0.00% | 0.00 | 0 |
14DN | 1414 Degrees Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14DO | 1414 Degrees Limited | 0.008 | 0.00 | 0.00% | 0.00 | 0 |
1AD | AdAlta Limited | 0.019 | 0.00 | 0.00% | 0.00 | 0 |
13S | 13 Seeds Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
NEW YORK, N.Y., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) (the “Company”), a provider of data management services to healthcare providers, announced today that it has regained compliance with The Nasdaq Stock Market’s (“Nasdaq”) continued listing requirements regarding periodic reporting. On April 17, May 17, and August 19, 2024, Nasdaq notified the Company that it no longer met the Nasdaq’s periodic filing requirement under Listing Rule 5250(c)(1) (the “Rule”). In a letter dated October 14, 2024, Nasdaq indicated that based on the September 24, October 10, and October 11, 2024, filing of ...
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly pursue broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies and post-transplant maintenance setting – – Kura anticipates collaboration funding along with current cash balance to support AML program ...
BEIJING, Nov. 20, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the third quarter ended September 30, 2024.
LAV321demonstrated strong results in its third consecutive year of field trials in Europe REHOVOT, Israel, Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeting downy mildew. Over three years of field trials across Europe, evaluating the efficacy of LAV321 in protecting crops from fungal diseases, LAV321 demonstrated an impressive average efficacy rate of 70% against downy mildew in grapes. These results lead to the decision to advance it to the last stage of product development toward ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 94,240.42 | 1,899.35 | 2.06% | 1.86T | 10,091,270,512 |
ETH | Ethereum | 3,073.48 | -36.80 | -1.18% | 370.19B | 3,563,413,411 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 119.66B | 1,026,959,285 |
SOL | Solana | 235.69 | -2.28 | -0.96% | 110.57B | 2,309,206,717 |
BNB | Binance Coin | 609.79 | -6.12 | -0.99% | 96.26B | 344,553,967 |
XRP | Ripple | 1.11 | 0.010 | 0.91% | 62.79B | 1,354,725,084 |
DOGE | Dogecoin | 0.37795 | -0.01313 | -3.36% | 55.19B | 3,095,680,415 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 35.56B | 1,780,671,867 |
STETH | stETH | 3,070.59 | -37.65 | -1.21% | 30.26B | 4,217,879 |
ADA | Cardano | 0.8143 | 0.0749 | 10.13% | 28.97B | 1,050,756,450 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions